KidneyIntelX
Healthcare Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5-7 Cranwood St, London, Greater London,...Phone Number
+44 7748960970Website
www.kidneyintelx.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About KidneyIntelX
Renalytix specializes in kidney health solutions, offering products like KidneyIntelX and kidneyintelX.dkd that assess the risk of progressive kidney function decline in patients with type 2 diabetes and early-stage chronic kidney disease. Their innovative approach focuses on preemptive, precision-based kidney care, aiming to improve patient outcomes through early risk identification. The company targets clinicians and patients, providing tools and resources to manage kidney health effectively. With FDA approval for kidneyintelX.dkd, Renalytix is committed to transforming the management of diabetic kidney disease.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is KidneyIntelX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if KidneyIntelX had a recent Job posting/layoffs
Check out if KidneyIntelX is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when KidneyIntelX launches new products
Funding: Get notified immidiatlly once KidneyIntelX has new funding data
KidneyIntelX, which may be a good buyer, showed buying intent in Masked Content Topic
Check if KidneyIntelX has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on KidneyIntelX recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at KidneyIntelX
Recommended Actions
Find VP level buyers at KidneyIntelX
Find more new buyers
Compare Similar Companies to KidneyIntelX
Compare insights from companies similar to KidneyIntelX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
KidneyIntelX
$7.8M
51-200
Private
-
-
N/A
Company Profile Activity
Activity Insights
KidneyIntelX is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
KidneyIntelX is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about KidneyIntelX.
KidneyIntelX Tech Stack
A closer look at the technologies used by KidneyIntelX
KidneyIntelX News & Media
KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences
Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patients Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patientsRenalytix plc (RNLX) Q3 2023 Earnings Call Transcript
Renalytix plc (NASDAQ:NASDAQ:RNLX) Q3 2023 Results Conference Call June 9, 2023 8:30 AM ETCompany ParticipantsPeter DeNardo - CapComm PartnersJames McCullough - CEOTom McLain -...Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2023.Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage
Read more news
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding KidneyIntelX
Sign Up For FreeTo access detailed company insights
Renalytix specializes in kidney health solutions, offering products like KidneyIntelX and kidneyintelX.dkd that assess the risk of progressive kidney function decline in patients with type 2 diabetes and early-stage chronic kidney disease. Their innovative approach focuses on preemptive, precision-based kidney care, aiming to improve patient outcom... Read More
